Research programme: bone cell regulators - Bone Medical

Drug Profile

Research programme: bone cell regulators - Bone Medical

Alternative Names: BN 005; BN 008

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bone Medical
  • Developer Bone Medical; University of Queenslands Institute for Molecular Bioscience
  • Class Peptides
  • Mechanism of Action Osteoblast stimulants; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Osteoporosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Osteoporosis in Australia
  • 28 Jan 2013 Early research is ongoing in Australia
  • 13 Aug 2007 Early research in Osteoporosis in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top